We noted a dose-dependent improvement in biochemical parameters of T1D including suppression of putatively pathogenic Th17.1 immune cells and reduction of proinsulin-specific IFN-γ and IL-17A-producing T cells that have previously been implicated in the pathogenesis of T1D. The gene discussed is IL17A; the disease is type 1 diabetes mellitus.